Alzheimer’s blood test, Aducanumab approval issues, Medicare coverage of brain scans that diagnose dementia, Some at higher risk for Alzheimer’s
Decision-making on antipsychotic medication use in assisted living needs system-level perspective: study
By
Kimberly Bonvissuto
Jan 25, 2023
Decisions on administering as-needed antipsychotic medications in assisted living/ residential care communities are based on attitudes, underlying morality and perceived expertise, requiring a system-level...
Hearing loss linked to increased risk for dementia
Jan 12, 2023
The authors say that the findings support public health action to improve hearing aid access.
Social isolation tied to higher dementia risk
Jan 11, 2023
The risk was found to be similar across racial and ethnic groups of older adults in the United States.
Vascular risk factors only explain part of Alzheimer’s disease risk for Blacks, Hispanics
Jan 11, 2023
Barriers to healthcare access and other socioeconomic factors may increase vulnerability in racial/ethnic minorities.
Social isolation contributes to increased likelihood of dementia: study
By
Kimberly Bonvissuto
Jan 11, 2023
Social isolation is common among older adults in the United States — experienced by one in four of them — and increases the likelihood of developing dementia, according to the results of a new study.
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.
Natural environments may cut hospitalization for patients with neurodegenerative diseases
Dec 30, 2022
The normalized difference vegetation index was negatively associated with hospitalization for Alzheimer’s disease and related dementia as well as Parkinson’s disease.
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
Senior living celebrates ‘big wins’ in proposed $1.7 trillion omnibus package
By
Kimberly Bonvissuto
Dec 21, 2022
Senior living advocates are claiming “major victories” for the industry following the release of the proposed $1.7 trillion congressional year-end spending bill on Monday.